{
  "trial_id": "NCT03131960",
  "study_characteristics": {
    "title": "Vagus nerve stimulation paired with rehabilitation for upper limb motor function after ischaemic stroke (VNS-REHAB): a randomised, blinded, pivotal, device trial",
    "design": "randomised, triple-blind, sham-controlled trial",
    "sample_size": 108,
    "sample_size_by_group": [
      {
        "group": "VNS group",
        "n": 53
      },
      {
        "group": "control group",
        "n": 55
      }
    ],
    "follow_up_duration_month": 4.4,
    "publication_year": 2021,
    "geographic_location": "UK and USA",
    "journal_name": "The Lancet",
    "author_info": {
      "primary_author": "Jesse Dawson",
      "primary_author_email": "jesse.dawson@glasgow.ac.uk",
      "affiliation": "University of Glasgow"
    },
    "funding_source": {
      "source": "MicroTransponder",
      "details": "Funder participated in study design and manuscript writing, no role in data collection/analysis/interpretation"
    }
  },
  "population": {
    "name": "Participants with moderate-to-severe arm weakness at least 9 months after ischaemic stroke",
    "condition": "ischaemic stroke",
    "N": 108,
    "sex_ratio_male": 0.67,
    "baseline_characteristics": [
      {
        "name": "FMA-UE score",
        "group": "VNS group",
        "value_text": "Not reported",
        "unit": "points"
      },
      {
        "name": "FMA-UE score",
        "group": "control group",
        "value_text": "Not reported",
        "unit": "points"
      },
      {
        "name": "Age, years",
        "group": "VNS group",
        "value": 59.1,
        "unit": "years"
      },
      {
        "name": "Age, years",
        "group": "control group",
        "value": 61.1,
        "unit": "years"
      },
      {
        "name": "Male sex proportion",
        "group": "VNS group",
        "value": 0.64,
        "unit": "proportion"
      },
      {
        "name": "Male sex proportion",
        "group": "control group",
        "value": 0.65,
        "unit": "proportion"
      },
      {
        "name": "Race",
        "group": "VNS group",
        "value_text": "White 79%, African American 17%, Asian/Indian/other 2%, Not reported 2%"
      },
      {
        "name": "Race",
        "group": "control group",
        "value_text": "White 78%, African American 16%, Asian/Indian/other 7%, Not reported 2%"
      },
      {
        "name": "Time since stroke, years",
        "group": "VNS group",
        "value": 3.1,
        "unit": "years"
      },
      {
        "name": "Time since stroke, years",
        "group": "control group",
        "value": 3.3,
        "unit": "years"
      },
      {
        "name": "Handedness",
        "group": "VNS group",
        "value_text": "Right 91%, Left 8%, Ambidextrous 2%"
      },
      {
        "name": "Handedness",
        "group": "control group",
        "value_text": "Right 91%, Left 9%"
      },
      {
        "name": "Side of paresis",
        "group": "VNS group",
        "value_text": "Right 47%, Left 53%"
      },
      {
        "name": "Side of paresis",
        "group": "control group",
        "value_text": "Right 47%, Left 53%"
      },
      {
        "name": "FMA-UE baseline score",
        "group": "VNS group",
        "value": 34.4,
        "unit": "score"
      },
      {
        "name": "FMA-UE baseline score",
        "group": "control group",
        "value": 35.7,
        "unit": "score"
      },
      {
        "name": "WMFT-Functional baseline score",
        "group": "VNS group",
        "value": 2.71,
        "unit": "score"
      },
      {
        "name": "WMFT-Functional baseline score",
        "group": "control group",
        "value": 2.83,
        "unit": "score"
      }
    ],
    "disease_classification": {
      "name": "ischaemic stroke",
      "severity": "moderate-to-severe"
    },
    "target_population_age": ">30 years (stratified, but no mean provided)",
    "target_population_characteristics": "long-term upper limb motor impairment after stroke"
  },
  "intervention": [
    {
      "group": "VNS group",
      "treatment": "active vagus nerve stimulation paired with rehabilitation",
      "dose": "0.8 mA, 100 µs, 30 Hz stimulation pulses",
      "freq": "three times per week",
      "route": "implanted device",
      "duration_weeks": 6.0,
      "intervention_type": "medical_device"
    },
    {
      "group": "VNS",
      "treatment": "vagus nerve stimulation",
      "dose": "0.8 mA (adjustable for comfort)",
      "freq": "per movement repetition",
      "route": "implanted device",
      "duration_weeks": 6.0,
      "intervention_type": "medical_device"
    },
    {
      "group": "Sham",
      "treatment": "sham stimulation",
      "dose": "0 mA",
      "freq": "per movement repetition",
      "route": "implanted device",
      "duration_weeks": 6.0,
      "intervention_type": "other"
    },
    {
      "group": "Intervention group",
      "treatment": "Vagus nerve stimulation paired with upper-limb rehabilitation",
      "dose": "Not specified",
      "freq": "Not specified"
    }
  ],
  "comparator": [
    {
      "group": "control group",
      "treatment": "sham stimulation paired with rehabilitation",
      "placebo": true,
      "comparator_type": "placebo"
    },
    {
      "group": "Sham",
      "treatment": "sham stimulation",
      "placebo": true,
      "standard_care": false,
      "comparator_type": "placebo",
      "number_of_comparators": 1
    },
    {
      "group": "Sham group",
      "treatment": "Sham stimulation",
      "placebo": true,
      "comparator_type": "placebo"
    }
  ],
  "baseline_outcomes": [
    {
      "name": "FMA-UE score",
      "outcome_type": "baseline",
      "time_point": "baseline",
      "unit": "score",
      "group_results": [
        {
          "group": "VNS group",
          "value": 34.4
        },
        {
          "group": "control group",
          "value": 35.7
        }
      ]
    },
    {
      "name": "WMFT-Functional score",
      "outcome_type": "baseline",
      "time_point": "baseline",
      "unit": "score",
      "group_results": [
        {
          "group": "VNS group",
          "value": 2.71
        },
        {
          "group": "control group",
          "value": 2.83
        }
      ]
    }
  ],
  "primary_outcomes": [
    {
      "name": "Change in Fugl-Meyer Assessment-Upper Extremity (FMA-UE) score",
      "outcome_type": "primary",
      "time_point": "first day after completion of in-clinic therapy",
      "unit": "points",
      "group_results": [
        {
          "group": "VNS group",
          "value": 5.0
        },
        {
          "group": "control group",
          "value": 2.4
        }
      ],
      "comparisons": [
        {
          "group1": "VNS group",
          "group2": "control group",
          "p_value": 0.0014
        }
      ],
      "timepoint_month": 1.5
    },
    {
      "name": "Change in FMA-UE score",
      "outcome_type": "primary",
      "time_point": "1 day after therapy",
      "unit": "score change",
      "group_results": [
        {
          "group": "VNS group",
          "value": 5.0
        },
        {
          "group": "control group",
          "value": 2.4
        }
      ],
      "comparisons": [
        {
          "group1": "VNS group",
          "group2": "control group",
          "p_value": 0.0014
        }
      ],
      "ci95_lower": 1.0,
      "ci95_upper": 4.2
    }
  ],
  "secondary_outcomes": [
    {
      "name": "FMA-UE response rate",
      "outcome_type": "secondary",
      "time_point": "90 days after in-clinic therapy",
      "unit": "%",
      "group_results": [
        {
          "group": "VNS group",
          "value": 47.0
        },
        {
          "group": "control group",
          "value": 24.0
        }
      ],
      "comparisons": [
        {
          "group1": "VNS group",
          "group2": "control group",
          "p_value": 0.0098
        }
      ],
      "timepoint_month": 4.5
    },
    {
      "name": "Change in FMA-UE score",
      "outcome_type": "secondary",
      "time_point": "90 days after therapy",
      "unit": "score change",
      "group_results": [
        {
          "group": "VNS group",
          "value": 5.8
        },
        {
          "group": "control group",
          "value": 2.8
        }
      ],
      "comparisons": [
        {
          "group1": "VNS group",
          "group2": "control group",
          "p_value": 0.0077
        }
      ],
      "ci95_lower": 0.8,
      "ci95_upper": 5.1,
      "timepoint_month": 3.0
    },
    {
      "name": "FMA-UE response rate (≥6-point change)",
      "outcome_type": "secondary",
      "time_point": "90 days after therapy",
      "unit": "%",
      "group_results": [
        {
          "group": "VNS group",
          "value": 47.0
        },
        {
          "group": "control group",
          "value": 24.0
        }
      ],
      "comparisons": [
        {
          "group1": "VNS group",
          "group2": "control group",
          "p_value": 0.0098
        }
      ],
      "timepoint_month": 3.0
    },
    {
      "name": "Change in WMFT-Functional score",
      "outcome_type": "secondary",
      "time_point": "90 days after therapy",
      "unit": "score change",
      "group_results": [
        {
          "group": "VNS group",
          "value": 0.5
        },
        {
          "group": "control group",
          "value": 0.2
        }
      ],
      "comparisons": [
        {
          "group1": "VNS group",
          "group2": "control group",
          "p_value": 0.0001
        }
      ],
      "ci95_lower": 0.16,
      "ci95_upper": 0.43,
      "timepoint_month": 3.0
    },
    {
      "name": "WMFT-Functional response rate (≥0.4-point change)",
      "outcome_type": "secondary",
      "time_point": "90 days after therapy",
      "unit": "%",
      "group_results": [
        {
          "group": "VNS group",
          "value": 57.0
        },
        {
          "group": "control group",
          "value": 22.0
        }
      ],
      "comparisons": [
        {
          "group1": "VNS group",
          "group2": "control group",
          "p_value": 0.0001
        }
      ],
      "timepoint_month": 3.0
    }
  ],
  "safety_outcomes": [
    {
      "name": "Serious adverse events",
      "outcome_type": "safety",
      "time_point": "during study",
      "unit": "count",
      "group_results": [
        {
          "group": "VNS group",
          "value": 0.0
        },
        {
          "group": "control group",
          "value": 1.0
        }
      ]
    },
    {
      "name": "Participants with at least one adverse event",
      "outcome_type": "safety",
      "time_point": "during study",
      "unit": "participants",
      "group_results": [
        {
          "group": "VNS group",
          "value": 43.0
        },
        {
          "group": "control group",
          "value": 42.0
        }
      ]
    },
    {
      "name": "Number of severe adverse events",
      "outcome_type": "safety",
      "time_point": "during study",
      "unit": "events",
      "group_results": [
        {
          "group": "VNS group",
          "value": 3.0
        },
        {
          "group": "control group",
          "value": 2.0
        }
      ]
    },
    {
      "name": "Participants with adverse events related to device implantation",
      "outcome_type": "safety",
      "time_point": "during study",
      "unit": "participants",
      "group_results": [
        {
          "group": "VNS group",
          "value": 21.0
        },
        {
          "group": "control group",
          "value": 24.0
        }
      ]
    },
    {
      "name": "Participants with adverse events related to device use",
      "outcome_type": "safety",
      "time_point": "during study",
      "unit": "participants",
      "group_results": [
        {
          "group": "VNS group",
          "value": 13.0
        },
        {
          "group": "control group",
          "value": 9.0
        }
      ]
    },
    {
      "name": "Serious adverse events",
      "outcome_type": "safety",
      "time_point": "During treatment",
      "unit": "count",
      "group_results": [
        {
          "group": "VNS group",
          "value": 0.0
        },
        {
          "group": "Sham group",
          "value": 0.0
        }
      ]
    },
    {
      "name": "Vocal cord palsy",
      "outcome_type": "safety",
      "time_point": "During treatment",
      "unit": "rate",
      "group_results": [
        {
          "group": "VNS group"
        },
        {
          "group": "Sham group"
        }
      ]
    }
  ],
  "follow_up_month": 12.0
}